Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Sei Investments Co. purchased a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 60,795 shares of the company’s stock, valued at approximately $102,000. Sei Investments Co. owned about 0.12% of ALX Oncology at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Barclays PLC boosted its holdings in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after buying an additional 42,185 shares in the last quarter. Wellington Management Group LLP raised its holdings in ALX Oncology by 15.2% during the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock worth $305,000 after buying an additional 22,114 shares during the period. Verition Fund Management LLC increased its position in shares of ALX Oncology by 308.4% in the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock worth $242,000 after acquiring an additional 100,454 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of ALX Oncology by 16.9% during the fourth quarter. Los Angeles Capital Management LLC now owns 301,419 shares of the company’s stock valued at $503,000 after acquiring an additional 43,640 shares during the period. Finally, JSF Financial LLC purchased a new stake in shares of ALX Oncology in the 4th quarter valued at approximately $29,000. 97.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ALXO. Jefferies Financial Group upgraded ALX Oncology from a “hold” rating to a “buy” rating and lifted their price target for the company from $2.00 to $3.00 in a report on Thursday, March 6th. Stifel Nicolaus lowered their target price on ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research note on Friday, March 7th. Piper Sandler boosted their price target on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. Finally, UBS Group reduced their price target on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a report on Monday, January 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.14.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $0.49 on Friday. The firm has a market capitalization of $26.16 million, a PE ratio of -0.16 and a beta of 1.20. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology Holdings Inc. has a 1 year low of $0.46 and a 1 year high of $17.83. The firm’s fifty day simple moving average is $0.87 and its 200 day simple moving average is $1.33.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.